sitagliptin + metformin hydrochloride +pharma 50 mg + 1000 mg tabletki powlekane
+pharma arzneimittel gmbh - sitagliptini hydrochloridum monohydricum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
sitagliptin + metformin hydrochloride +pharma 50 mg + 850 mg tabletki powlekane
+pharma arzneimittel gmbh - sitagliptini hydrochloridum monohydricum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
tenofovir disoproxil accordpharma 245 mg tabletki powlekane
accord healthcare polska sp. z o.o. - tenofovirum disoproxilum - tabletki powlekane - 245 mg
eprocliv 850 mg + 50 mg tabletki powlekane
sandoz gmbh - metformini hydrochloridum + sitagliptinum - tabletki powlekane - 850 mg + 50 mg
eprocliv 1000 mg + 50 mg tabletki powlekane
sandoz gmbh - metformini hydrochloridum + sitagliptinum - tabletki powlekane - 1000 mg + 50 mg
sademlip 50 mg + 850 mg tabletki powlekane
sandoz gmbh - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
sademlip 50 mg + 1000 mg tabletki powlekane
sandoz gmbh - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
veyvondi
baxalta innovations gmbh - vonicog alfa - choroby von willebranda - antykrościeryczne - veyvondi wskazany dla osób dorosłych (w wieku 18 lat i starszych) w chorobie von willebranda (vwd), gdy desmopresyna (ddavp) jeden leczenie jest nieskuteczne lub nie jest wskazany w leczeniu krwawień i chirurgicznego krwawienie - zapobieganie chirurgicznego krwawienie. veyvondi nie powinny być stosowane w leczeniu hemofilii a.
lenalidomide sandoz 7,5 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 7,5 mg
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Środki przeciwnowotworowe - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.